Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells

The PI3K-Akt pathway together with one of its downstream targets, the mechanistic target of rapamycin (mTOR; also known as the mammalian target of rapamycin) is a highly deregulated pathway in cancers. mTOR exists in two complexes, mTORC1 and mTORC2. Akt phosphorylated at T308 inhibits TSC1/2 complex to activate mTORC1; mTORC2 is recognized as the kinase phosphorylating Akt at S473. Inhibition of autophagy by mTORC1 was shown to rescue disheveled (Dvl) leading to activation of Wnt pathway. Cyclin D1 and the c-Myc are activated by the Wnt signaling. Cyclin D1 is a key player in initiation of cell cycle. c-Myc triggers metabolic reprograming in G1 phase of cell cycle, which also activates the transcription factors like FoxO and p53 that play key roles in promoting the progression of cell cycle. While the role of p53 in cancer cell metabolism in arresting glycolysis and inhibition of pentose phosphate pathway has come to be recognized, there are confusions in the literature on the role of FoxO and that of rictor. FoxO was shown to be the transcription factor of rictor, in addition to the cell cycle inhibitors like p21. Rictor has dual roles; inhibition of c-Myc and constitution of mTORC2, both of which are key factors in the exit of G1-S phase and entry into G2 phase of cell cycle. A model is presented in this article, which suggests that the PI3K-Akt-mTOR and Wnt pathways converge and regulate the progression of cell cycle through G0-G1-S-phases and reprogram the metabolism in cancer cells. This model is different from the conventional method of looking at individual pathways triggering the cell cycle.

[1]  David R. Bowler,et al.  The Nuts and Bolts , 2013 .

[2]  John A Foley,et al.  Nuts and bolts. , 2013, Connecticut medicine.

[3]  A. Levine,et al.  Proliferation and tissue remodeling in cancer: the hallmarks revisited , 2012, Cell Death and Disease.

[4]  R. DePinho,et al.  FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. , 2012, The Journal of clinical investigation.

[5]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[6]  C. Talchai,et al.  Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure , 2012, Cell.

[7]  K. Mahajan,et al.  PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics , 2012, Journal of cellular physiology.

[8]  J. Powell,et al.  All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells , 2012, Front. Immun..

[9]  O. Delpuech,et al.  FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression , 2011, Cell Death and Differentiation.

[10]  Zhiwei Wang,et al.  An evolving role for DEPTOR in tumor development and progression. , 2012, Neoplasia.

[11]  Paul Polakis,et al.  Wnt signaling in cancer. , 2012, Cold Spring Harbor perspectives in biology.

[12]  S. Johansson,et al.  Receptor-Specific Mechanisms Regulate Phosphorylation of AKT at Ser473: Role of RICTOR in β1 Integrin-Mediated Cell Survival , 2012, PloS one.

[13]  C. Dessy,et al.  Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. , 2012, Cancer research.

[14]  Zheng Guo,et al.  Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. , 2012, Biochemical and biophysical research communications.

[15]  M. Radi,et al.  ATP-competitive inhibitors of mTOR: an update. , 2011, Current medicinal chemistry.

[16]  L. Pickering,et al.  Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. , 2011, Future oncology.

[17]  Daniel J. Klionsky,et al.  Relieving Autophagy and 4EBP1 from Rapamycin Resistance , 2011, Molecular and Cellular Biology.

[18]  M. Lu,et al.  Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. , 2011, The Journal of clinical investigation.

[19]  Carlos A. Garcia,et al.  Convergence of the Mammalian Target of Rapamycin Complex 1- and Glycogen Synthase Kinase 3-β–Signaling Pathways Regulates the Innate Inflammatory Response , 2011, The Journal of Immunology.

[20]  C. Weihl Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. , 2011, Current Alzheimer research.

[21]  J. McCubrey,et al.  Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia , 2011, Leukemia.

[22]  Randy L. Johnson,et al.  Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size , 2011, Science.

[23]  E. E. Vincent,et al.  Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer , 2011, British Journal of Cancer.

[24]  E. Goncharova,et al.  mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells , 2011, Molecular and Cellular Biology.

[25]  R. Hajjar,et al.  Resistin Promotes Cardiac Hypertrophy via the AMP-activated Protein Kinase/Mammalian Target of Rapamycin (AMPK/mTOR) and c-Jun N-terminal Kinase/Insulin Receptor Substrate 1 (JNK/IRS1) Pathways* , 2011, The Journal of Biological Chemistry.

[26]  G. Condorelli,et al.  IκB kinase ε and TANK-binding kinase 1 activate AKT by direct phosphorylation , 2011, Proceedings of the National Academy of Sciences.

[27]  V. Deretic Autophagy in immunity and cell‐autonomous defense against intracellular microbes , 2011, Immunological reviews.

[28]  E. Gottlieb p53 guards the metabolic pathway less travelled , 2011, Nature Cell Biology.

[29]  A. Mancuso,et al.  p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase , 2011, Nature Cell Biology.

[30]  C. Eng,et al.  Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. , 2011, Cancer letters.

[31]  Karen H. Vousden,et al.  Metabolic regulation by p53 , 2011, Journal of Molecular Medicine.

[32]  Chien-Hung Chen,et al.  ER Stress Inhibits mTORC2 and Akt Signaling Through GSK-3β–Mediated Phosphorylation of Rictor , 2011, Science Signaling.

[33]  B. Viollet,et al.  AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.

[34]  Yongqiang Chen,et al.  The regulation of autophagy – unanswered questions , 2011, Journal of Cell Science.

[35]  D. Steiner,et al.  GSK-3 inactivation or depletion promotes β-cell replication via down regulation of the CDK inhibitor, p27 (Kip1) , 2011, Islets.

[36]  Stuart H. Orkin,et al.  A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.

[37]  D. Klionsky,et al.  Eaten alive: a history of macroautophagy , 2010, Nature Cell Biology.

[38]  Xu Zhang,et al.  Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation , 2010, Nature Cell Biology.

[39]  Novel inhibitors of mTORC1 and mTORC2. , 2010, Current opinion in investigational drugs.

[40]  V. De Pinto,et al.  VDAC, a multi-functional mitochondrial protein regulating cell life and death. , 2010, Molecular aspects of medicine.

[41]  Ye Guang Chen,et al.  Dishevelled: The hub of Wnt signaling. , 2010, Cellular signalling.

[42]  N. Hay,et al.  FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. , 2010, Developmental cell.

[43]  A. Marette,et al.  Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. , 2010, Molecular endocrinology.

[44]  D. Sabatini,et al.  Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids , 2010, Cell.

[45]  M. Magnuson,et al.  Fat Cell–Specific Ablation of Rictor in Mice Impairs Insulin-Regulated Fat Cell and Whole-Body Glucose and Lipid Metabolism , 2010, Diabetes.

[46]  Mark H. Ellisman,et al.  Sestrin as a Feedback Inhibitor of TOR That Prevents Age-Related Pathologies , 2010, Science.

[47]  Dianqing Wu,et al.  GSK3: a multifaceted kinase in Wnt signaling. , 2010, Trends in biochemical sciences.

[48]  J. Downward,et al.  Rictor is a novel target of p70 S6 kinase-1 , 2010, Oncogene.

[49]  Cam Patterson,et al.  The FoxO family in cardiac function and dysfunction. , 2010, Annual review of physiology.

[50]  M. Swami MYC matters. , 2010, Nature reviews. Cancer.

[51]  D. Alessi,et al.  The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.

[52]  Philippe P Roux,et al.  mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling , 2009, Molecular and Cellular Biology.

[53]  B. Burgering,et al.  Should I stay or should I go: beta-catenin decides under stress. , 2009, Biochimica et biophysica acta.

[54]  M. Stipanuk Macroautophagy and its role in nutrient homeostasis. , 2009, Nutrition reviews.

[55]  R. Abraham,et al.  Targeting mTOR globally in cancer: Thinking beyond rapamycin , 2009, Cell cycle.

[56]  D. Sabatini,et al.  mTOR signaling at a glance , 2009, Journal of Cell Science.

[57]  J. Asara,et al.  Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.

[58]  R. Lothe,et al.  Autophagy in tumour suppression and promotion , 2009, Molecular oncology.

[59]  Mina J Bissell,et al.  Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. , 2009, Cancer research.

[60]  J. Blenis,et al.  Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.

[61]  Simon Tavaré,et al.  Autophagy mediates the mitotic senescence transition. , 2009, Genes & development.

[62]  S. Lowe,et al.  Eating to exit: autophagy-enabled senescence revealed. , 2009, Genes & development.

[63]  Yu Deng,et al.  RhoA Regulates G1-S Progression of Gastric Cancer Cells by Modulation of Multiple INK4 Family Tumor Suppressors , 2009, Molecular Cancer Research.

[64]  H. Lane,et al.  Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition , 2009, Molecular Cancer Therapeutics.

[65]  N. Hay,et al.  Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.

[66]  H. Lane,et al.  Increased AKT S 473 phosphorylation after mTORC 1 inhibition is rictor dependent and does not predict tumor cell response to PI 3 K / mTOR inhibition , 2009 .

[67]  Jianping Ye,et al.  S6K Directly Phosphorylates IRS-1 on Ser-270 to Promote Insulin Resistance in Response to TNF-α Signaling through IKK2* , 2008, Journal of Biological Chemistry.

[68]  M. Essers,et al.  Interaction of FOXO with β-Catenin Inhibits β-Catenin/T Cell Factor Activity* , 2008, Journal of Biological Chemistry.

[69]  Ji-yong Wang,et al.  Nuclear Dvl, c-Jun, β-catenin, and TCF form a complex leading to stabiLization of β-catenin–TCF interaction , 2008, The Journal of cell biology.

[70]  T. Tsuruo,et al.  FOXO transcription factor-dependent p15INK4b and p19INK4d expression , 2008, Oncogene.

[71]  A. Giordano,et al.  From G0 to S phase: A view of the roles played by the retinoblastoma (Rb) family members in the Rb‐E2F pathway , 2007, Journal of cellular biochemistry.

[72]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.

[73]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[74]  A. Lipovsky,et al.  S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. , 2006, Molecular cell.

[75]  J. Baselga,et al.  Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer , 2006, Cancer.

[76]  J. Qin,et al.  SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.

[77]  Ming You,et al.  TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth , 2006, Cell.

[78]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[79]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[80]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[81]  D. Kwiatkowski,et al.  Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. , 2005, Human molecular genetics.

[82]  F. Liu,et al.  PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. , 2005, American journal of physiology. Endocrinology and metabolism.

[83]  J. Martínez,et al.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15 , 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[84]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[85]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[86]  R. Nusse,et al.  Wnt signaling in disease and in development , 2005, Cell Research.

[87]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[88]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[89]  R. DePinho,et al.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. , 2004, Genes & development.

[90]  H. Saya,et al.  Down‐regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1‐dependent DNA‐damage checkpoint signals contributes to cell cycle arrest at G1/S transition , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[91]  N. Sonenberg,et al.  Signaling from Akt to FRAP/TOR Targets both 4E-BP andS6K in Drosophilamelanogaster , 2003, Molecular and Cellular Biology.

[92]  C. Downes,et al.  Redox regulation of PI 3‐kinase signalling via inactivation of PTEN , 2003, The EMBO journal.

[93]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  M. Mita,et al.  The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer , 2003, Cancer biology & therapy.

[95]  C. Clevenger Signal transduction. , 2003, Breast disease.

[96]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[97]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[98]  C. Martínez-A,et al.  Forkhead transcription factors contribute to execution of the mitotic programme in mammals , 2001, Nature.

[99]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[100]  A. Kimmel,et al.  GSK3, a master switch regulating cell-fate specification and tumorigenesis. , 2000, Current opinion in genetics & development.

[101]  T. Kurosaki,et al.  The Inositol Phosphatase SHIP Inhibits Akt/PKB Activation in B Cells* , 1998, The Journal of Biological Chemistry.

[102]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[103]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[104]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[105]  P. Moore,et al.  Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization. , 1996, Genomics.

[106]  R. Abraham,et al.  Immunopharmacology of rapamycin. , 1996, Annual review of immunology.

[107]  J. Downward A target for Pl(3) kinase , 1995, Nature.

[108]  J. Downward Signal transduction. A target for PI(3) kinase. , 1995, Nature.

[109]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[110]  J. Testa,et al.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.

[111]  J. Woodgett,et al.  Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. , 1991, European journal of biochemistry.

[112]  R. Weinberg,et al.  c‐myc and c‐fos expression in differentiating mouse primary keratinocytes. , 1986, The EMBO journal.

[113]  R. Weinberg,et al.  Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts , 1986, Molecular and cellular biology.

[114]  G. Gill,et al.  The EGF receptor: structure, regulation and potential role in malignancy. , 1985, Cancer surveys.

[115]  J. Mendelsohn,et al.  Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. , 1983, Molecular biology & medicine.

[116]  J. Hartley,et al.  Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[117]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.